Rebecca T. Horwitz
Bartlit Beck LLP, 2013-Present, Partner (since 2019)
Cases tried or otherwise taken to judgment
Merck & Cie v. Watson Labs (D. Del., 2015)
Trial counsel for Merck & Cie and its exclusive licensee Bayer in Hatch-Waxman litigation against challenger seeking to market generic versions of the oral contraceptives Beyaz® and Safyral®. Complete trial victory for Merck and Bayer; case settled.
Drake v. Allergan (D. Vermont, 2014)
Trial Counsel for Allergan in case involving claim that BOTOX® caused pediatric patient treated for muscle spasticity to experience seizures. Cross-examined life-care expert. Following a two-week trial, jury returned verdict for plaintiffs. Case settled during appeal.
Regents of the University of Minnesota v. Gilead Sciences (N.D. Cal.)
Counsel for Gilead in patent infringement action related to Gilead’s hepatitis C treatments. Case Pending.
ViiV Healthcare v. Gilead Sciences (D. Del.)
Counsel for Gilead in patent infringement case related to Gilead’s Biktarvy® HIV treatment. Case pending.
Other representative cases
Gilead Sciences v. Mylan Pharmaceuticals (D. Del.)
Trial counsel for Gilead in Hatch-Waxman litigation relating to Evotaz®, an HIV treatment containing atazanavir and cobicistat.
U.S. Airways v. Sabre Inc. (S.D.N.Y. 2011-present)
Counsel for Sabre in U.S. Airways' antitrust action concerning Sabre's Global Distribution System.
Botox Litigation (Nationwide, 2013-2015)
Counsel for Allergan in cases involving allegations that BOTOX® causes various injuries. Obtained favorable settlements in three of the four cases in which we represent Allergan. Tried the fourth case to a jury verdict for plaintiffs.
- Merck & Cie, et. al. v. Watson Labs (Beyaz®/Safyral® Litigation) (D. Del. 2015)